Research programme: myocardial derived insulin-like growth factor 1 therapy - Cardium Therapeutics

Drug Profile

Research programme: myocardial derived insulin-like growth factor 1 therapy - Cardium Therapeutics

Alternative Names: Ad5IGF-1; mdIGF-1

Latest Information Update: 25 Mar 2014

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Taxus Cardium Pharmaceuticals Group
  • Class Gene therapies
  • Mechanism of Action Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postmyocardial infarction

Most Recent Events

  • 25 Mar 2014 Discontinued - Preclinical for Postmyocardial infarction in USA (Intracoronary)
  • 17 Mar 2014 Cardium Therapeutics is now called Taxus Cardium Pharmaceuticals Group Inc.
  • 31 Dec 2011 No development reported - Preclinical for Postmyocardial infarction in USA (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top